In this issue:
Outcomes and risk stratification of early-stage melanoma micrometastases
Indications for sentinel node biopsy in early-stage melanoma
Therapeutic value of sentinel lymph node biopsy
T-VEC + pembrolizumab for advanced melanoma
Histopathological and immunological response to T-VEC
Scalp melanomas and brain metastases
Lenvatinib + pembrolizumab after progression on PD-1/ PD-L-1 inhibitor
Encorafenib + binimetinib vs vemurafenib/encorafenib in BRAF V600-mutant melanoma
Oestrogen receptors and melanoma in women
Predicting RFS in stage III melanoma treated with adjuvant immunotherapy
Please login below to download this issue (PDF)